

DR. ERIC WILLIAM HALL (Orcid ID : 0000-0003-0244-7458)

Article type : Original

**Title:** County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017

**Authors:** Eric W. Hall<sup>1</sup>, PhD, MPH; Sarah Schillie<sup>2</sup>, MD, MPH, MBA; Adam S. Vaughan<sup>3</sup>, PhD, MPH; Jeb Jones<sup>1</sup>, PhD, MPH, MS; Heather Bradley<sup>4</sup>, PhD, MHS; Ben Lopman<sup>1</sup>, PhD, MS; Eli Rosenberg<sup>5</sup>, PhD; Patrick Sullivan<sup>1</sup>, DVM, PhD.

<sup>1</sup>Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia

<sup>2</sup>Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia

<sup>3</sup>Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

<sup>4</sup>Department of Epidemiology & Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia

<sup>5</sup>Department of Epidemiology & Biostatistics, School of Public Health, University at Albany, Albany, New York

**Keywords:** death rates; public health; HCV; vital statistics; spatiotemporal model

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1002/HEP.31756](https://doi.org/10.1002/HEP.31756)

This article is protected by copyright. All rights reserved

Accepted Article

**Corresponding Author**

Eric Hall

1518 Clifton Road

Rollins School of Public Health

Emory University

Atlanta, GA 30329

Phone: 505-699-3501

Fax: 404-712-8392

eric.w.hall@emory.edu

**Abbreviations:** HCV, hepatitis C virus; CDC, Centers for Disease Control and Prevention; HHS, Department of Health and Human Services; ICD-10, International Classification of Diseases Tenth Revision; MCMC, Markov chain Monte Carlo; CI, credible interval; DAA, direct-acting antiviral.

**Financial Support:** This work was supported by the Center for AIDS Research at Emory University (P30AI050409)

**Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

## Abstract

Since 2013, the national HCV death rate has steadily declined, but this decline has not been quantified or described on a local level. We estimated county-level HCV death rates and assessed trends in HCV mortality from 2005 to 2013 and 2013 to 2017. We used mortality data from National Vital Statistics Systems and a Bayesian multivariate space-time conditional autoregressive model to estimate age-standardized HCV death rates from 2005 through 2017 for 3115 U.S. counties. Additionally, we estimated county-level age-standardized rates for persons <40 and 40+ years of age. We used log-linear regression models to estimate average annual percent change in HCV mortality during periods of interest and compared county-level trends to national trends. Nationally, the age-adjusted HCV death rate peaked in 2013 at 5.20 HCV deaths per 100,000 (95% credible interval, CI: 5.12, 5.26) before decreasing to 4.34 per 100,000 persons (95% CI: 4.28, 4.41) in 2017 (average annual percent change -4.69, 95%CI: -5.01, -4.33). County-level rates revealed heterogeneity in HCV mortality (2017 median rate=3.66, interdecile range: 2.19, 6.77), with the highest rates concentrated in the West, Southwest, Appalachia and northern Florida. Between 2013 and 2017, HCV mortality decreased in 80.0% (n=2274) of all U.S. counties with a reliable trend estimate, with 25.8% (n=803) of all counties experiencing a decrease larger than the national decline. Conclusion: Although many counties have experienced a shift in HCV mortality trends since 2013, the magnitude and composition of that shift have varied by place. These data provide a better understanding of geographic differences in HCV mortality and can be used by local jurisdictions to evaluate HCV mortality in their areas relative to surrounding areas and the nation.

In the United States, infection with hepatitis C virus (HCV) is the leading cause of morbidity and mortality from liver disease and was listed as an underlying or contributing cause of death in over 15,000 deaths in 2018.(1) From 1999 to 2013, the national HCV-associated death rate increased each year(2) and by 2013, the annual number of deaths attributable to HCV infection outnumbered deaths from all other notifiable infectious diseases combined.(3) Although data from the National Vital Statistics System indicate the national HCV death rate has declined since 2013(4), there has not been a trend analysis that quantifies change in HCV mortality since 2013.

In recent years, there have been shifts in the epidemiological nature of the HCV epidemic, advancement in treatment options, and changes in public health strategies, all of which are likely to impact HCV mortality. Although HCV infections are still disproportionately concentrated among adults born between 1945 and 1965(5), rising acute HCV incidence rates among adults <40 years of age(6) have led to emergence of a bimodal epidemic by age group. Despite the substantial prevalent burden and recent rise in HCV incidence rates, the availability of accurate diagnostic testing and curative therapy has the public health community targeting the elimination of HCV infection as a public health problem in the United States.(7, 8) In the United States, strategic plans by Centers for Disease Control and Prevention (CDC)(9) and the Department of Health and Human Services (HHS)(10) have specifically identified reductions in the national HCV death rate as an indicator to monitor progress toward achieving these goals. For example, CDC's Viral Hepatitis National Progress Report 2020 Goal was to reduce the national age-adjusted HCV death rate below 4.17 per 100,000 persons(4) by 2020.

Although there is evidence the epidemiology of hepatitis C differs by location, small-area spatial differences in HCV mortality are not well described(11). Of the estimated 2.4 million adults who were living with a chronic HCV infection during 2013-2016(12), over half lived in just nine states.(13) Analysis of newly reported acute and chronic HCV cases from surveillance data has shown dramatic regional differences in HCV incidence trends.(14) To our knowledge, HCV-related death rates and mortality trends have not been systematically characterized on a local level. Previous research on small-area stroke(15) and heart disease mortality(16, 17) has demonstrated that merely describing changes in national death rates may conceal important trends occurring at the local level. Furthermore, many public health initiatives are implemented at the county or local level, and

describing geographic disparities in HCV mortality can help inform the utilization of available interventions.

This analysis had two primary objectives. First, we aimed to estimate annual county-level HCV death rates between 2005 and 2017. Second, to better understand local changes in HCV mortality, we assessed county-level trends from 2005 to 2013 and 2013 to 2017.

## **Methods**

### *Data Source*

Data are from the National Vital Statistics System Detailed Multiple Cause of Death micro-data files.(18) All data were obtained under a data use agreement with the National Center for Health Statistics and analysis was conducted before 2018 data were released.(19) Using codes from the International Classification of Diseases Tenth Revision (ICD-10)(20), we identified the annual number of deaths that listed HCV (ICD-10 codes B17.1 and B18.2) as a multiple cause of death in the record axis fields for each county and demographic group of interest during 2000 to 2017. Annual county-level deaths were tabulated for all 36 combinations of the following demographic groups: race (black, white, other), sex (male, female) and age (0-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years and 60+ years)(21). We used National Center for Health Statistics bridged-race annual county-level population estimates(22) for population denominators in all death rates. Due to changes in county definitions over this time period (i.e. the creation and consolidation of counties), we combined counties common set of 3115 counties in this analysis. Institutional review board approval was not required because this analysis only used publicly available restricted-use county-level data.

### *Estimating Death Rates and Percent Change*

We used a Bayesian multivariate space-time conditional autoregressive model to model the annual number of HCV deaths for each group in each county. The details of this model, which has primarily been used to estimate stroke(15) and heart disease death rates(16, 23), have been previously described.(24) Briefly, it is a conditional autoregressive model for spatially referenced count data that incorporates correlations across space, time and demographic groups. By iteratively estimating parameters and shrinking the random effects for each county toward values for neighboring counties

(defined using first order queen contiguity) and years, the Bayesian model produces estimates that are more precise than those that would be produced from other small area analysis methods that do not incorporate information from neighboring counties.(25) Each model was fit with a Markov chain Monte Carlo (MCMC) algorithm using user-developed code in R v3.5.0.

We aggregated the modeled counts to estimate overall and age-stratified (<40 years and 40+ years) county-level HCV death rates for the years 2005 through 2017. While we incorporated data from 2000 to 2017, we limited results to years after 2005 because HCV infections are disproportionately concentrated among persons born in 1945-1965(5), and all persons in this high burden cohort were 40+ years of age from 2005 onward. We estimated county-level rates using the medians of the posterior MCMC distributions and the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles were used to calculate 95% credible intervals (95% CI). Additionally, county-level counts were aggregated to estimate national HCV death rates for each year. To facilitate comparison across place and time, all estimated rates were standardized to the age distribution of the 2000 U.S. standard population.(26)

To calculate trends, we included the estimated county rates for all years of interest in separate log-linear regression models for each MCMC iteration and each county. Average annual percent change was estimated as the median trend of all MCMC iterations within each county and the corresponding 95% CI was calculated using the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentile values. National data has shown that HCV death rates across the country were increasing prior to 2013 and have declined each year thereafter.(4) Therefore, we estimated national and county-level HCV mortality trends for 2005-2013 and 2013-2017. Furthermore, we compared county-level trends from 2013-2017 to the estimated national decline during that time period and categorized counties into the following four groups: decrease faster than national (i.e., average annual percent change is below the lower bound of the national 95% CI), decrease similar to national (i.e., average annual percent change is within 95% CI of national decline), decrease slower than national (i.e., average annual percent change is between the upper bound of national decline and zero) and increase (i.e., average annual percent change is greater than zero). By using the posterior distributions to calculate percent change and to compare against the national average, these calculations account for the uncertainty in the underlying rates.

To assess spatiotemporal trends in HCV mortality, we mapped overall and age-stratified (<40 years and 40+ years) 2017 HCV death rates by quintiles. Additionally, we mapped overall county-level average annual percent change in HCV death rates from 2005-2013 and 2013-2017 and HCV mortality trends relative to the national decline from 2013-2017.

#### *Data Suppression*

Any county-level rate that had a CI width larger than the point estimate was considered unreliable.(27) If a county had one or more unreliable HCV death rate between 2005 and 2017, estimated rates and trends for that county were not reported. Additionally, if a county had one or more unreliable rate for either age group in 2017, all age-stratified rates were suppressed for that county. To protect privacy, NCHS data suppression standards require the suppression of any tabulated crude counts that total less than 10. In this work, we do not report crude counts and only report modeled estimates so that individuals are not identifiable in these data. These criteria resulted in reliable rates for a common set of counties for all years of overall rates (n=2839, 91.1% of all counties) and a common set of counties for all age-stratified 2017 rates (n=2570, 82.5%).

#### **Results**

In 2017, the estimated national age-adjusted HCV death rate was 4.34 per 100,000 persons (95% CI: 4.28, 4.41, Table 1). From 2005 to 2017, the overall national HCV death rate was highest in 2013 at 5.20 HCV deaths per 100,000 (95% CI: 5.12, 5.26). On average, national HCV mortality increased by 3.17% each year (95% CI: 3.00, 3.34) from 2005 to 2013 before decreasing 4.69% each year (4.33, 5.01) from 2013 to 2017. For all years, the HCV death rate was much higher among adults 40+ years of age (9.77 per 100,000 in 2017; 95% CI: 9.65, 9.94) compared to persons <40 years of age (0.23 per 100,000, 95%CI: 0.22, 0.24).

#### *County-level HCV Death Rates and Trends*

The overall median county-level HCV death rate was lower than the national average (2017 median rate=3.66, interdecile range: 2.19, 6.77). In 2017, 61.0% (n=1732) of counties with reliable rate estimates had an age-adjusted HCV death rate lower than the National Progress Report 2020 Goal of 4.17 per 100,000(4) (Supplemental Table 1). The spatial pattern of HCV death rates in 2017

indicated the highest rates are primarily concentrated in the West, Southwest, Appalachia and northern Florida (Figure 1). Stratifying the 2017 HCV death rates by age group reveals the emergence of some key spatial trends. The highest burden of HCV death rates among persons <40 years of age occurred in New Mexico, Oklahoma and Appalachia, primarily in a geographic band that stretches from Tennessee through Pennsylvania (Figure 2). In contrast, the highest burden of HCV deaths among adults 40+ were concentrated along the West coast in and in the southwest.

Of the 2839 counties with reliable rate estimates for all years, HCV mortality increased in 95.3% (n=2705) of counties from 2005 to 2013. Counties that did not experience an increase in HCV death rates during this timeframe were primarily centered around urban areas, such as St. Louis, New Orleans, Miami, Washington, D.C., and New York City (Figure 3). In contrast, 80.0% (n=2274) of counties with a reliable trend estimate experienced a decrease in HCV mortality between 2013 and 2017. A total of 803 counties (25.8%) had a decline in HCV mortality that was faster than the national decline (average annual percent change between 4.33% and 5.01%) during this time period (Figure 4). Many of these counties were located in the plains states, in Michigan and Wisconsin and in the northeast. Counties that had an increase in HCV mortality during this time frame were concentrated in Oklahoma, Texas and parts of Appalachia stretching from Kentucky up through western Pennsylvania. The majority of urban areas that experienced a decrease in HCV mortality from 2005 to 2013 continued that trend from 2013 to 2017. The notable exception are the counties around New Orleans, in which HCV death rates increased between 2013 and 2017.

Figure 5 displays a hexamap of the estimated national HCV death rates per 100,000 persons to visualize age-period-cohort trends(28). The figure contains three axes representative of age (in single years), birth cohort and year. The highest HCV death rates are concentrated among persons born between 1945-1960.

## **Discussion**

These results illustrate a widespread shift in HCV mortality trends since 2013, but the magnitude and composition of that shift have occurred differently by place and age group. Prior to 2013, increases in HCV death rates were widespread throughout the country. Although national HCV mortality trends reversed in 2013, there is much more heterogeneity in recent trends at the county-level. Since 2013,

decreasing national trends are driven primarily by large, decreasing HCV death rates in the West, Southwest and Northeast. However, roughly 1 in 5 counties have experienced an increase in HCV death rates during this same time period and these counties are disproportionately concentrated in Texas, Oklahoma and Appalachia and the counties surrounding New Orleans.

There are a few possible explanations for the reversal of HCV mortality trends since 2013. First, as a result of elevated underlying prevalence and years of targeted screening, the majority of diagnosed chronic HCV infections are among adults born between 1945 and 1965.<sup>(5)</sup> Additionally, from 2013-2016, only 62% of HCV infected persons in this age group were aware of their infection, indicating there are many more undiagnosed infections<sup>(29)</sup>. As members of this birth cohort aged and the severity of their infections progressed, HCV death rates were expected to increase. Accordingly, after a large proportion of this high burden birth cohort dies, overall HCV death rates are expected to fall. The pattern seen in Figure 5 illustrates this birth-cohort effect. Second, since the introduction of curative treatment in the form of direct-acting antiviral (DAAs) agents in 2011, there is some evidence that mortality due to HCV-related cirrhosis has been decreasing on the national-level.<sup>(30)</sup> Given that DAAs can cure approximately 90% of persons with an HCV-infection within 8-12 weeks with a well-tolerated oral therapy regimen, their introduction would be expected to lower HCV-related mortality.<sup>(31)</sup> However, access to treatment is not widespread<sup>(32)</sup>, and the short time frame makes it difficult to attribute county-level declines in HCV mortality to successful treatment initiatives. It is important to note that earlier this year, both CDC<sup>(32)</sup> and the United States Preventive Services Task Force<sup>(33)</sup> updated their respective screening guidelines to recommend HCV screening at least once in a lifetime for all adults 18 years of age or older<sup>(32)</sup>, and it is unclear how this will impact current HCV mortality trends. Although adherence to guidelines should theoretically result in the identification of additional HCV infections, which could potentially increase HCV death rates, it should also result in additional persons receiving therapy, which could decrease HCV mortality. The continued monitoring of trends in county-level HCV death rates can provide additional insight on the impact new guidelines may have on mortality.

In addition to understanding trends in HCV mortality, the spatial distribution of age-specific HCV death rates provides additional cross-sectional insight on the current HCV epidemic. HCV death rates are much higher in adults 40+ years of age throughout the time frame of interest, which aligns with

expectations for two reasons. First, for all years of study in this analysis, the well-described high-burden birth cohort (born 1945-1965) is included in the older age group. Second, the progression of chronic liver disease caused by HCV infection develops slowly and significant liver fibrosis does not usually occur before 20 years.(32) Although the magnitude and variability in county-level HCV death rates is much smaller among persons <40 years of age, the spatial pattern provides additional emphasis areas of concern for increasing HCV incidence rates among young adults. Counties in the highest quintile of HCV death rates among persons <40 are disproportionately concentrated in Appalachia (from Tennessee up through Pennsylvania) and Oklahoma, which are areas that have been known to be impacted by increases in injection drug use as a result of the opioid crisis and rising viral hepatitis incidence rates.(14, 34, 35)

The combined interpretation of cross-sectional death rates and temporal trends provides geographic context to the current bimodal nature of the HCV epidemic. As previously noted, in 2017 the highest HCV death rates were concentrated in the West, Southwest, Appalachia and northern Florida, but age-stratification and trend analysis reveal differences between these regions. For example, high overall county-level HCV death rates in the West and Southwest have primarily been driven by high rates among older (40+ years) adults, and these rates are declining. This is in contrast to many of the counties in Appalachia, in which the overall HCV death rate is increasing and seems to be driven by high HCV mortality among persons aged <40 years. Finally, there are select counties around Oklahoma and northern New Mexico in which high HCV mortality is occurring in older adults and emerging among persons under 40 years. This emergence of HCV mortality among adults <40 provides additional support for the expansion of HCV screening recommendations to include adults of all ages.(32)

Importantly, these results provide an additional granular data point that can be used to better understand the distribution of viral hepatitis infection in general. Systematic, accurate and timely measurements of incidence, prevalence and mortality are essential for describing the epidemiological burden of any health condition, but these indicators are not consistently available on a small geographic scale for viral hepatitis. State health departments are responsible for identifying and reporting incident HCV cases, but many states lack adequate funding, and surveillance practices are inconsistent across jurisdictions.(36) Nationally representative survey data has been used in small-

area estimation models to estimate state-level HCV prevalence(13), but updates to those estimates are reliant on model assumptions, and long delays between survey cycles limit utility. Although these results do not replace the need for a comprehensive and cohesive viral hepatitis surveillance system, these granular and temporal data on HCV mortality provide an important metric for understanding the evolution of the HCV epidemic.

In addition to using the HCV-related death rate as a key indicator in monitoring progress of national viral hepatitis action plans(9, 10), local jurisdictions can use these data to evaluate HCV mortality in their area relative to surrounding areas and the nation as a whole. A better understanding of where high HCV mortality is occurring can inform the allocation of public health resources and interventions that aim to reduce HCV mortality or infection. For example, providing HCV screening along with medication assisted treatment and syringe-service programs has been shown to be a cost-effective strategy in reducing HCV infection.(37) As the HCV epidemic continues to evolve and injection drug use continues to drive HCV transmission, these data can help inform where syringe service programs, or any other interventions that increase access to HCV screening or linkage to care, should be located.

#### *Limitations*

The main limitation of this study is the potential for misclassification of HCV-related deaths through the use of death certificate data. Although deaths that include an HCV death code are not expected to be misclassified, viral hepatitis is often undiagnosed and underreported as cause of death on death certificates.(38) The degree to which HCV is undiagnosed and underreported on death certificate may differ across jurisdictions, which would impact county-level results. However, this method of death classification has been constant over time and changes in underreporting would be unlikely to explain temporal trends. As universal HCV screening recommendations are implemented, the underdiagnosis of HCV is expected to decrease in future years. Finally, these estimated HCV death rates have not been compared to jurisdiction-based data. Although these comparison data are limited, a formal comparison would further validate these results.

Additionally, data in the National Vital Statistics System includes all recorded deaths in the United States, which reduces concerns about selection bias or generalizability. Age-standardized death rates

may not be equivalent to actual observed death rates, but age-standardization was appropriate in this analysis for comparisons across the population and time as the age-distribution of the population changes. Finally, previous work has indicated that race/ethnicity and sex disparities in chronic HCV prevalence differ on the state-level(39), and there may also be demographic disparities in county-level mortality trends. Future research should explore and quantify demographic disparities in these spatiotemporal trends.

### *Conclusion*

Hepatitis C death rates have been declining since 2013, but the direction and magnitude of that trend is not consistent by place or age group. Efforts to continue the national decline in HCV mortality will require innovative approaches that increase access to testing and care for persons living with HCV infection, particularly in counties in which HCV death rates continue to remain high.

### **References**

1. Centers for Disease Control and Prevention. WONDER, Multiple Cause of Death, 1999-2018. In: U.S. Department of Health and Human Services, editor. Atlanta, GA; 2020.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med* 2012;156:271-278.
3. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated With Hepatitis C Virus in the United States, 2003-2013. *Clin Infect Dis* 2016;62:1287-1288.
4. Centers for Disease Control and Prevention. National Progress Report 2020 Goal: Reduce the rate of hepatitis C-related deaths to 4.17 per 100,000 population. In; 2020.  
<https://www.cdc.gov/hepatitis/policy/NationalProgressReport-HepC-ReduceDeaths.htm>
5. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *MMWR Recomm Rep* 2012;61:1-32.
6. Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018. *MMWR. Morbidity and mortality weekly report* 2020;69:399-404.

7. National Academies of Sciences E, Medicine: Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. In: Buckley GJ, Strom BL, eds. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington (DC): National Academies Press (US) Copyright 2016 by the National Academy of Sciences. All rights reserved., 2016.
8. National Academies of Sciences E, Medicine: A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. In: Strom BL, Buckley GJ, eds. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington (DC): National Academies Press (US) Copyright 2017 by the National Academy of Sciences. All rights reserved., 2017.
9. Centers for Disease Control and Prevention. Division of Viral Hepatitis (DVH) Strategic Plan, 2016-2020: Bringing Together Science and Public-Health Practice for the Elimination of Viral Hepatitis.; 2016.
10. Department of Health and Human Services. National Viral Hepatitis Action Plan 2017-2020. In; 2017.
11. Ly KN, Miniño AM, Liu SJ, Roberts H, Hughes EM, Ward JW, Jiles RB. Deaths Associated With Hepatitis C Virus Infection Among Residents in 50 States and the District of Columbia, 2016–2017. *Clinical Infectious Diseases* 2019.
12. Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, Edlin BR, et al. Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016. *Hepatology* 2018.
13. Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, et al. Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. *JAMA Netw Open* 2018;1:e186371.
14. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged  $\leq 30$  years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. *MMWR Morb Mortal Wkly Rep* 2015;64:453-458.
15. Hall EW, Vaughan AS, Ritchey MD, Schieb L, Casper M. Stagnating National Declines in Stroke Mortality Mask Widespread County-Level Increases, 2010-2016. *Stroke* 2019;50:3355-3359.
16. Vaughan AS, Ritchey MD, Hannan J, Kramer MR, Casper M. Widespread recent increases in county-level heart disease mortality across age groups. *Ann Epidemiol* 2017;27:796-800.
17. Vaughan AS, Schieb L, Casper M. Historic and recent trends in county-level coronary heart disease death rates by race, gender, and age group, United States, 1979-2017. *PLOS ONE* 2020;15:e0235839.

18. National Vital Statistics System (NVSS). Mortality Data. In; 2020.
19. National Center for Health Statistics. Data Release Policy for Vital Statistics Micro-data Files. In; 2020.
20. World Health Organization. International statistical classification of diseases and related health problems: World Health Organization, 2004.
21. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance, United States, 2017: Division of Viral Hepatitis; 2019.
22. National Center for Health Statistics. US Census populations with bridged race categories. In; 2020.
23. Vaughan AS, Quick H, Schieb L, Kramer MR, Taylor HA, Casper M. Changing rate orders of race-gender heart disease death rates: An exploration of county-level race-gender disparities. *SSM Popul Health* 2019;7:100334.
24. Quick H, Waller LA, Casper M. A multivariate space–time model for analysing county level heart disease death rates by race and sex. *Journal of the Royal Statistical Society: Series C (Applied Statistics)* 2018;67:291-304.
25. Vaughan AS, Kramer MR, Waller LA, Schieb LJ, Greer S, Casper M. Comparing methods of measuring geographic patterns in temporal trends: an application to county-level heart disease mortality in the United States, 1973 to 2010. *Ann Epidemiol* 2015;25:329-335.e323.
26. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected U.S. population. *Healthy People 2010 Stat Notes* 2001:1-10.
27. Centers for Disease Control and Prevention. United States Cancer Statistics (USCS): Suppression of Rates and Counts. In; 2018.
28. Jalal H, Burke D. Hexamaps for Visualizing Age-Period-Cohort Data Trends. In: medRxiv; 2019.
29. Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey. *J Viral Hepat* 2019.
30. Kim D, Li AA, Perumpail BJ, Gadiparthi C, Kim W, Cholankeril G, Glenn JS, et al. Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States. *Hepatology* 2019;69:1064-1074.
31. Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. *Wellcome open research* 2019;4:132-132.

32. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020. *MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports* 2020;69:1-17.
33. U.S. Preventive Services Task Force (USPSTF). Final Recommendation Statement: Hepatitis C Virus Infection in Adolescents and Adults: Screening. In; 2020.
34. Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, et al. County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States. *J Acquir Immune Defic Syndr* 2016;73:323-331.
35. Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, Tressler S, Vellozzi C. Increases in Acute Hepatitis B Virus Infections - Kentucky, Tennessee, and West Virginia, 2006-2013. *MMWR Morb Mortal Wkly Rep* 2016;65:47-50.
36. Moore MS, Greene SK, Bocour A, Brown CM, Coyle JR, Kuncio D, Onofrey S, et al. Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates. *J Viral Hepat* 2019.
37. Barbosa C, Fraser H, Hoerger TJ, Leib A, Havens JR, Young A, Kral A, et al. Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs. *Addiction* 2019;114:2267-2278.
38. Moorman AC, Rupp LB, Gordon SC, Zhong Y, Xing J, Lu M, Boscarino JA, et al. Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings. *Infect Dis Clin North Am* 2018;32:253-268.
39. Bradley H, Hall EW, Rosenthal EM, Sullivan PS, Ryerson AB, Rosenberg ES. Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016. *Hepatology Communications* 2020;4:355-370.

## Figure Legends

*Figure 1. Age-Standardized HCV Death Rates, by U.S. County, 2017.* Any counties that have at least one unreliable rate estimate between 2005 and 2017 are suppressed as unreliable.

*Figure 2. Age-Standardized HCV Death Rates by Age Group, U.S. Counties, 2017.* Any counties that have an unreliable 2017 rate for either age group are suppressed as unreliable in both panels. All rates are age-adjusted to the 2000 U.S. Standard Population. Scales for each map differ.

*Figure 3. Average Annual Percent Change in HCV Death Rates, All Ages, by U.S. County.* Any counties that have at least one unreliable rate estimate between 2005 and 2017 are suppressed as unreliable. All rates are age-adjusted to the 2000 U.S. Standard Population. Scales for each map differ.

*Figure 4. Change in County-level HCV Death Rates Relative to National Trend, 2013-2017.* Counties that have an estimated average annual percent change that is within the 95% credible interval of the estimated national average annual percent change (-5.01% to -4.33%) are categorized as decreasing at a pace similar to the national trend. To present a consistent set of counties, any counties that have at least one unreliable rate estimate between 2000 and 2017 are suppressed as unreliable. All rates are age-adjusted to the 2000 U.S. Standard Population. Values inside parentheses indicate the percent of counties that are included in each category.

*Figure 5. Hexamap of birth-year cohort patterns in HCV Death Rates, United States, 1999-2018.* Abbreviations: C, birth year cohort; P, period (i.e. year); A, age.



Table 1. Estimated Age-Standardized National and County-Level Hepatitis C Death Rates and Percent Change, United States, 2005–2017.

<b>Rates</b>	<i>National</i>			<i>County-level</i>		
	<b>rate</b>	<b>95% CI</b>		<b>median</b>	<b>IDR</b>	
<i>All ages</i>						
2005 rate (per 100,000)	3.83	3.77	3.89	2.93	1.75	5.03
2013 rate (per 100,000)	5.20	5.12	5.26	4.12	2.52	7.40
2017 rate (per 100,000)	4.34	4.28	4.41	3.66	2.19	6.77
<i>&lt;40 years old</i>						
2005 rate (per 100,000)	0.27	0.26	0.27	0.24	0.19	0.33
2013 rate (per 100,000)	0.18	0.17	0.19	0.19	0.15	0.25
2017 rate (per 100,000)	0.23	0.22	0.24	0.24	0.18	0.36
<i>40+ years old</i>						
2005 rate (per 100,000)	8.56	8.40	8.68	6.49	3.80	11.27
2013 rate (per 100,000)	11.84	11.65	11.98	9.33	5.65	16.83
2017 rate (per 100,000)	9.77	9.65	9.94	8.19	4.80	15.35
<b>Trends (all ages)</b>						
<i>AAPC (%)</i>						
2005 to 2013	+3.17	+3.00	+3.34	+4.11	+0.97	+7.19
2013 to 2017	-4.69	-5.01	-4.33	-3.09	-7.36	+1.92
<i>Absolute change (per 100,000)</i>						
2005 to 2013	+1.37	+1.26	+1.46	+1.13	+0.38	+2.85
2013 to 2017	-0.86	-0.93	-0.76	-0.40	-1.30	+0.37

Abbreviations: CI, credible interval; IDR, inter-decile range (10<sup>th</sup> and 90<sup>th</sup> percentiles);



AAPC, average annual percent change

# Hepatitis C Death Rates, 2017





hep\_31756\_f1.eps

## Hepatitis C Death Rates, 2017 <40 years





## Hepatitis C Death Rates, 2017 40+ years





hep\_31756\_f2.eps

## Percent Change in Hepatitis C Death Rates, 2005-2013




## Percent Change in Hepatitis C Death Rates, 2013-2017



hep\_31756\_f3.eps

# Change in Hepatitis C Death Rates Relative to National Trend 2013-2017



- Decrease faster than national (25.8%)
- Decrease similar to national (7.1%)
- Decrease slower than national (40.1%)
- Increase (18.1%)
- Unreliable Estimate (8.9%)

hep\_31756\_f4.eps

